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Abstract This study was designed to display the molec-
ular genetic features of short-term survivors in glioblasto-
mas with oligodendroglioma component (GBMO). A total
of 186 patients with histological diagnosis of primary gli-
omas, including 11 GBMO-STS (short-term survivors,
survival B12 months), 29 GBMO-LTS (relatively long-
term survivors, survival [12 months), 36 anaplastic oli-
goastrocytoma (AOA) and 110 glioblastoma multiforme
(GBM), enrolled in the study. An evaluation form was
developed and used to document molecular pathological,
clinical and treatment-associated parameters between sub-
groups. Kaplan–Meier plots for survival showed that the
median progression-free survival (PFS) and overall sur-
vival (OS) of GBMO-STS were 5.0 and 10.0 months,
respectively. Intergroup comparison revealed that the
GBMO-STS harbored the most dismal prognosis than those
with AOA, GBMO-LTS or GBM (P \ 0.001 for PFS,
P \ 0.001 for OS, respectively). Cox regression analyses
revealed that 1p/19q co-deletion and 19p polysomy were
independent prognostic factors (P \ 0.05). Pearson’s Chi
square test demonstrated GBMO-STS exhibited lower 1p/
19q co-deletion, IDH1 mutation rates than AOA or
GBMO-LTS (P = 0.032, P = 0.045 for 1p/19q co-dele-
tion; P = 0.034, P = 0.005 for IDH1 mutation,
respectively) but higher chromosome 1q, 19p polysomy
rates compared with AOA or GBM (P = 0.037, P = 0.030
for 1q polysomy; P = 0.017, P = 0.011 for 19p polysomy,
respectively). Patients with glioblastomas with oligoden-
droglioma component concurrent with polysomy for
chromosomes 1 and 19 always confers an unfavorable
prognosis which needs our extra attention in clinic.
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Introduction
The latest WHO classification of tumors of central nervous
system (CNS) introduced an entity–AOA with necrosis was
to be diagnosed as glioblastomas with oligodendroglioma
component (GBMO). As a new pathology entity, the
studies devoted to revealing the prognosis of GBMO were
relatively limited.
Increasing evidence suggested GBMO was a heteroge-
neous group with considerable survival variant. Several
reports found that the survival of GBMO was significantly
longer than glioblastoma multiforme (GBM) whose median
overall survival (OS) was only 12–15 months in spite of
multimodal aggressive treatment, comprising surgical
resection, local radiotherapy and systemic chemotherapy
[1–3]. Nevertheless, reports showed GBMO without sig-
nificant prognosis advantage over GBM were also con-
secutively published in the latest years [4–6]. In the present
study, we found a small fraction of patients who were
formerly diagnosed with AOA but displayed OS
B12 months. However, after the pathology re-evaluation,
all these patients were confirmed as AOA with necrosis
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which should be classified into GBMO according to the
latest WHO classification of CNS tumors.
GBMO displayed OS B12.0 months is a relatively rare
event which is worthy of further inquiry. It has not been
firmly established which, if any, of the molecular genetic
aberrations is important for the pathogenesis of GBMO-
STS represent prognostic factors. The identification of
molecular genetic markers that are associated with survival
in patients with GBMO would be beneficial for its diag-
nostic and prognostic potential. In this regard, we report a
retrospective analysis of 186 primary high-grade gliomas
recruited in the Beijing Tiantan Hospital Neurosurgery
Department. In addition to basic clinical data, we evaluate
the clinical characteristics and screen for glioma associated
genetic aberrations, i.e. 1p/19q co-deletion, IDH1 muta-
tion, MGMT promoter methylation, PTEN, p53, Ki-67,




A total of 186 patients (male 111 and female 75) with
histological diagnosis of primary supratentorial high-grade
gliomas (including 36 AOA, 11 GBMO-STS, 29 GBMO-
LTS and 110 GBM) in Beijing Tiantan Hospital from May
2008 to May 2011 were enrolled in the study. The sec-
ondary GBM were excluded. All patients provided written
informed consent for the current study and the clinical
study was approved by the Medical Ethics Committee of
Capital Medical University. The mean age of this cohort
was 47.5 ± 12.5 years at the time of surgery. All speci-
mens were independently re-evaluated by three experi-
enced neuro-pathologists according to the 2007 WHO
classification of the CNS tumors [7]. In case of a discrep-
ancy, the three observers simultaneously reviewed the
slides to achieve a consensus. Patients who underwent
needle biopsies prior resection, and/or prior adjuvant
therapy (radiotherapy or chemotherapy) were excluded.
These were done to create a more uniform patient popu-
lation which could be propitious to the study.
Treatment
All the patients with gliomas, in our institution, were
treated according to the National Comprehensive Cancer
Network (NCCN) guideline. Patients, in our department,
once pathologically diagnosed with high grade glioma,
systemic chemotherapy and radiotherapy will be attempted
after operation. Maximal tumor bulk resection while pre-
serving the vital eloquent cortex was the principle goal
during operation. Intraoperative subcortical electrical
stimulation was performed when necessary. Extent of
resection was assessed by the intraoperative ultrasound.
Postoperative radiotherapy was routinely delivered to
patients within 1 month after operation. The total dose was
60 Gy, which was divided into 30 daily fractions of 2 Gy
each. Meanwhile, postoperative chemotherapy was given;
the common course of chemotherapy was 4–6 cycles which
depended on the tolerance of toxic effect. The adjuvant
chemotherapy drugs were mainly nimustine (ACNU) or
temozolomide (TMZ).
Recorded variables
The clinical, operative, and hospital course records of 186
patients who met the inclusion criteria were retrospectively
reviewed. The following information was recorded
including patient’s age, gender, removal degree, location of
tumor, adjuvant therapy, and molecular parameters. The
molecular parameters in this study included 1p/19q, IDH1,
MGMT, PTEN, p53, Ki-67, EGFR, and VEGF. The status
of chromosomes 1 and 19 was detected by fluorescence
in situ hybridization (FISH) method, and IDH1 was
sequenced. PTEN, p53, Ki-67, EGFR, VEGF expression
were detected by immunohistochemical method. The
MGMT promoter methylation was analyzed by methyla-
tion-specific PCR (MSP).
Assessment of 1p/19q status by the fluorescence in situ
hybridization (FISH) method
1p/19q co-deletion was detected by FISH method as
described previously [8]. Tumors with more than 30 % of
nuclei showing DNA loss were defined as tumor with
chromosomal loss. The tumor was considered to have
polysomy if[30 % of nuclei showed more than two 1q and
19p signals.
IDH1 sequence analysis
Genomic DNA was isolated from snap-frozen tissue using
the QIAmp DNA mini-kit, as described by the manufac-
turer (Qiagen). A fragment of 254 bp length spanning the
catalytic domain of IDH1 including codon 132 was
amplified using the sense primer IDH1 F: 50-ACCAAAT
GGCACCATACG-30 and the antisense primer IDH1 R:
50-TTCATACCTTGCTTAATGGGG-30. PCR using stan-
dard buffer conditions, 30 ng of DNA and GoTaq DNA
Polymerase (TaKaRa, Japan) employed 35 cycles with
denaturing at 95 C for 30 s, annealing at 54 C for 45 s
and extension at 72 C for 50 s in a total volume of 25 lL.
The PCR amplification product was sent to Beijing Tianyi
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Huiyuan Bioscience and Technology Incorporation for
sequencing.
Immunohistochemical analysis
Evaluation of PTEN, p53, Ki-67, EGFR, VEGF was
detected by immunohistochemistry (IHC) as described
previously [9]. The expression levels were based on the
percentage of immunopositive cells (negative \10 % of
tumor cells; positive C10 % of tumor cells) (Table S1).
MGMT promoter methylation analysis
Genomic DNA was isolated from frozen tumor tissue by
using Qiagen kit (Qiagen, Valencia, CA). MGMT promoter
methylation was analyzed by MSP. Tumor DNA (2 lg) was
treated with sodium bisulfite using the CpG genome DNA
modification kit (Qiagen). The primer sequences for the
unmethylated reaction were 50-TTTGTGTTTTGATGTT
TGTAGGTTTTTGT-30 (forward) and 50-AACTCCACACT
CTTCCAAAAACAAAACA-30 (reverse). For the methyl-
ated reaction, they were 50-TTTCGACGTTCGTAGGTTT
TCGC-30 (forward) and 50-GCACTCTTCCGAAAACG
AAACG-30 (reverse). The annealing temperature was 59 C.
The PCR products were separated on 4 % agarose gels. The
investigators who selected and analyzed the glioblasoma
samples were blinded to all clinical information. Pyrose-
quencing analysis was carried out by Gene Tech (Shanghai)
Company Limited. The GBM samples [methylation values
(10 %)] were considered as being methylated.
Follow-up
The progression-free survival (PFS) was designated as the
time period from the first operation to the time of tumor
recurrence or evidence of progression based on magnetic
resonance imaging (MRI). Patients who were recurrence-
free at last follow-up were considered as a censored event
in analysis. OS was defined as the period between the first
operation and death or last follow-up. Patients who were
still alive at last follow-up were considered as a censored
event in analysis. All the survival data were collected
mainly when patients visited the clinics and during the
phone interview with patients and/or their relatives.
Statistical analysis
SPSS 13.0 (SPSS for Windows, version 13.0 [SPSS Inc.,
Chicago, IL, USA]) was used for statistical analysis.
Pearson’s Chi square test and Fisher’s exact test were used
to compare the frequencies between groups. Kaplan–Meier
method was used for survival analysis. Probability value
was obtained from two-sided tests, with a statistical sig-
nificance of P \ 0.05.
Results
Basic characteristics
The basic clinical characteristics of these patients enrolled
in the study were summarized in Table 1. A total of 186
patients with primary high-grade gliomas who were sur-
gically treated in our institution met the inclusion criteria.
There were 111 male and 75 female with a mean age of
47.5 ± 12.5 years old, including 36 (19.4 %) AOA, 11
(5.9 %) GBMO-STS, 29 (15.6 %) GBMO-LTS and 110
(59.1 %) GBM. The median follow-up period of the 186
patients was 13.5 months (range 1.0–42.0 months). A total
number of 94 patients had dead.
Survival analyses of AOA, GBMO-STS, GBMO-LTS
and GBM
In the cohort 186 high-grade glioma, univariate analysis
demonstrated that 1p/19q co-deletion, polysomy for 1q and
19p were associated with prognosis (P \ 0.05) (Fig. S1). In
multivariate Cox regression analysis, the presence of
1p/19q co-deletion and 19p polysomy were independent
prognostic factors (P \ 0.05) (Table 2). Unexpectedly, we
haven’t found the prognostic value of MGMT promoter
methylation, PTEN, p53, Ki-67, EGFR, VEGF expression
(P [ 0.05).
The median PFS and OS of GBMO-STS were 5.0 [95 %
CI 3.382–6.618] and 10.0 [95 % CI 7.977–12.023] months,
respectively, which were significantly shorter than AOA,
GBMO-LTS or GBM (P \ 0.001 for PFS, P \ 0.001 for
OS, respectively) (Fig. 1 and Table S2).
According to the status of chromosomes 1 and 19 (co-
deletion yes or no, and polysomy yes or no), we could
classified the 186 patients into four subgroups (subgroup 1,
without co-deletion or polysomy; subgroup 2, with co-
deletion but without polysomy; subgroup 3, with polysomy
but without co-deletion; subgroup 4, with polysomy and
co-deletion) which conferred different survival time.
Patients in subgroup 2 exhibited the most favorable prog-
nosis compared with subgroup 1, 3 and 4 (P \ 0.001 for
PFS, P = 0.002 for OS, respectively). Patients in subgroup
3 had the shortest survival time that the median PFS was
11.0 months and the OS was only 17.5 months. No sig-
nificant difference of prognosis was observed between
subgroup 1 and 4 (P = 0.803 for PFS, P = 0.868 for OS,
respectively) (Fig. 2).
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Frequencies of 1p/19q co-deletion, IDH1 mutation
and 1q, 19p polysomy in AOA, GBMO-STS, GBMO-
LTS and GBM
Fluorescence in situ hybridization (FISH) for chromo-
some 1p and 19q was available in 121 cases. Among
them, 28 (23.1 %) had 1p/19q co-deletion (including 14
in AOA, 0 in GBMO-STS, 11 in GBMO-LTS and 3 in
GBM). The frequencies of 1p/19q co-deletion in AOA,
GBMO-STS, GBMO-LTS and GBM were 40.0, 0.0 %,
37.9 and 6.5 %, respectively. The frequency of 1p/19q
co-deletion in GBMO-STS was significantly lower than
Table 1 Clinical characteristics of AOA, GBMO-STS, GBMO-LTS, and GBM














Median (range) 41.0 (14–58) 44.0 (30–68) 0.157 52.0 (12–70) 41.0 (14–58) 0.048* 43.0 (17–59) 41.0 (14–58) 0.348
Gender
Male (%) 6 (54.5) 18 (50.0) 70 (63.6) 6 (54.5) 17 (58.6) 6 (54.5)
Female (%) 5 (45.5) 18 (50.0) 0.792 40 (36.4) 5 (45.5) 0.789 12 (41.4) 5 (45.5) 1.0
Tumor location
Temporal (%) 4 (36.4) 9 (25.0) 41 (37.3) 4 (36.4) 10 (34.5) 4 (36.4)
Frontal (%) 4 (36.4) 15 (41.7) 37 (33.6) 4 (36.4) 11 (37.9) 4 (36.4)
Parietal (%) 2 (18.1) 5 (13.9) 17 (15.5) 2 (18.1) 4 (13.8) 2 (18.1)
Occipital (%) 0 (0.0) 1 (2.8) 4 (3.6) 0 (0.0) 0 (0.0) 0 (0.0)
Insular (%) 1 (9.1) 3 (8.3) 6 (5.5) 1 (9.1) 4 (13.8) 1 (9.1)
Others (%) 0 (0.0) 3 (8.3) [0.05 5 (4.5) 0 (0.0) [0.05 0 (0.0) 0 (0.0) [0.05
Preoperative epilepsy
Yes (%) 3 (27.3) 13 (36.1) 0.859 25 (22.7) 3 (27.3) 1.0 5 (20.7) 3 (27.3) 0.791
Preoperative KPS
Median (range) 80 (60–90) 75 (50–100) 0.768 80 (50–100) 80 (60–90) 0.369 80 (60–100) 80 (60–90) 0.677
Tumor resection
GTR (%) 6 (54.5) 25 (69.4) 0.583 52 (47.3) 6 (54.5) 0.645 18 (62.1) 6 (54.5) 0.942
Nimustine
Yes (%) 11 (100.0) 34 (94.4) 1.0# 106 (96.4) 11 (100.0) 1.0# 26 (89.7) 11 (100.0) 0.548#
Radiotherapy
Yes (%) 11 (100.0) 33 (91.7) 1.0# 102 (92.7) 11 (100.0) 1.0# 28 (96.6) 11 (100.0) 1.0#
Temozolomide
Yes (%) 7 (63.6) 11 (30.6) 0.105 59 (53.6) 7 (63.6) 0.525 21 (72.4) 7 (63.6) 0.877
KPS Karnofsky performance score, GTR gross-total resection
# Fisher’s exact test
* P \ 0.05
Table 2 Univariate and
multivariate associations with
survival for patients with high-
grade gliomas
N/A not available, OR odd ratio,
CI confidence interval
Parameter Univariate analysis P value Multivariate analysis P value
Median survival
(95 % CI) (months)
OR (95 % CI)
Factors associated with PFS
1p/19q co-deletion N/A \0.001 0.336 (0.176–0.643) 0.001
1q polysomy 9.0 (3.452–14.548) 0.003 –
19p polysomy 7.0 (4.798–9.202) \0.001 2.575 (1.608–4.124) \0.001
Factors associated with OS
1p/19q co-deletion N/A 0.003 0.319 (0.134–0.760) 0.010
1q polysomy 17.5 (13.404–21.596) 0.056 –
19p polysomy 17.0 (13.835–20.165) 0.009 1.930 (1.064–3.502) 0.031
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those in AOA or GBMO-LTS (P = 0.032 and
P = 0.045, respectively).
DNA sequencing for IDH1 was available in 137
patients. Among them, 38 out of 137 (27.7 %) had IDH1
mutation (including 14 in AOA, 0 in GBMO-STS, 16 in
GBMO-LTS and 8 in GBM). The frequencies of IDH1
mutation in AOA, GBMO-STS, GBMO-LTS and GBM
were 42.4, 0.0, 55.2 and 12.3 %, respectively. The
frequency of IDH1 mutation in GBMO-STS was signifi-
cantly lower than those in AOA or GBMO-LTS
(P = 0.034 and P = 0.005, respectively).
Chromosome polysomy status could be assessed in 123
patients. Of the 123 patients, 40 (32.5 %) had 1q ploy-
somy (including 8 in AOA, 7 in GBMO-STS, 13 in
GBMO-LTS and 12 in GBM); 46 (37.4 %) had 19p
ploysomy (including 9 in AOA, 8 in GBMO-STS, 16 in
Fig. 1 Kaplan–Meier plots for PFS and OS between AOA, GBMO-STS, GBMO-LTS and GBM were significantly different (P \ 0.001 for PFS,
P \ 0.001 for OS, respectively)
Fig. 2 Subgroup 1, without co-deletion or polysomy; Subgroup 2,
with co-deletion but without polysomy; Subgroup 3, with polysomy
but without co-deletion; Subgroup 4, with polysomy and co-deletion.
The survival time of subgroup 1 and 4 was significantly shorter
compared with subgroup 2 (P = 0.001 for PFS, P = 0.015 for OS,
respectively) but longer than subgroup 3 (P = 0.001 for PFS,
P = 0.05 for OS, respectively). No significant difference of prognosis
was observed between subgroup 1 and 4 (P = 0.803 for PFS,
P = 0.868 for OS, respectively)
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GBMO-LTS and 13 in GBM). 1q polysomy was slightly
more frequent in GBMO-STS compared with AOA or
GBM (P = 0.037 and P = 0.030, respectively). Further-
more, GBMO-STS exhibited higher 19p polysomy rate
than AOA or GBM (P = 0.017 and P = 0.011, respec-
tively) (Table 3).
Discussion
Anaplastic oligoastrocytoma (AOA) with necrosis, for-
merly categorized in WHO grade III, now is regarded as
GBMO (WHO grade IV) which is a heterogeneous group
with considerable survival variant. Several reports dedi-
cated to the survival analysis about GBM versus GBMO
showed that no favorable prognostic value of an oligo-
dendroglial component was found [4–6], although some
other studies indicated a longer survival for GBMO [1–3,
10] (Table 4). In the present study, we found a subtype
of GBMO harbored shorter survival time compared with
GBM. This is, so far as we know, the first series of
GBMO short-term survivors reported to date. We provide
a clinical characterization and report on molecular anal-
yses of the 11 patients who have a survival time
B12 months in order to reveal the reasons for the dismal
prognosis.
No significant difference in clinical characterization
was found between AOA, GBMO-STS, GBMO-LTS
and GBM
Considering variable prognostic factors such as the age of the
patients, extent of resection, postoperative radiotherapy or
chemotherapy, Karnofsky performance status (KPS) influ-
enced the patients’ survival, we recruited all the clinical
factors in the present study. We found that except for the age
at diagnosis of patients with GBM was older than those in
GBMO-STS (P = 0.048), no other significant difference
was observed between the four subgroups (AOA, GBMO-
STS, GBMO-LTS and GBM) (Table 1). But the prognosis of
patients with GBM was, unexpectedly, better than GBMO-
STS. It suggested the prognostic value of age was covered
after the adjustment for some potential prognostic factors,
such as 1p/19q co-deletion, polysomy for 1q and 19p, in
these high-grade gliomas.
High-frequency of 1p/19q co-deletion and IDH1
mutation result in the survival advantage of AOA
and GBMO-LTS
In our cohort, we found that the GBMO-STS exhibited
lower frequency of 1p/19q co-deletion than AOA or
GBMO-LTS but resembled it with GBM. This finding
Table 4 The outcomes of selected series of GBMO and GBM





Miller et al. [2] AOA with necrosis 71 N/A 22.8
GBM 581 N/A 9.8 \0.0001*
Vordermark et al. [1] GBMO 10 Post-OPT RT in 90 % ? ACNU and VM26 in 80 % 26.0 N/A
Kanno et al. [3] GBMO 17 Post-OPT RT ? ACNU ? TMZ &40.0a
GBM 52 Post-OPT RT ? ACNU ? TMZ &18.0a 0.068
Jiang et al. [10] GBMO 40 Post-OPT RT in 85 %; RT ? Chemo in 62 % 19.0
GBM 179 Post-OPT RT in 87 %; RT ? Chemo in 65 % 13.2 0.022*
Pinto et al. [4] GBMO 24 Post-OPT RT ? Chemo 14.9
GBM 64 Post-OPT RT ? Chemo 13.5 0.566
Hegi et al. [5] GBMO 52 Post-OPT RT ? Concomitant TMZ ? Ajuvand TMZ N/A
GBM 287 Post-OPT RT ? Concomitant TMZ ? Ajuvand TMZ N/A 0.48
Nakamura et al. [6] GBMO 19 Post-OPT RT in 100 % ? ACNU/TMZ in 89.5 % 14.0 N/A
Present study GBMO-STS 11 Post-OPT RT in 100 % ? ACNU
in 100 % ? TMZ in 63.6 %
10.0
GBMO-LTS 29 Post-OPT RT in 96.6 % ? ACNU
in 89.7 % ? TMZ in 72.4 %
18.5
GBM 110 Post-OPT RT in 92.7 % ? ACNU
in 96.4 % ? TMZ in 53.6 %
16.0 \0.001*
a Estimated value from graph
OPT operation, RT radiation therapy, Chemo chemotherapy, ACNU nimustine, TMZ temozolomide, N/A not available
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was similar with Jiang’s report, which maintained there
was no significant difference of 1p/19q co-deletion rate
between GBMO and GBM [10]. 1p/19q co-deletion is an
established genetic marker for prognostication about
glioma patients’ survival and chemosensitivity [11, 12].
In 1998, Cairncross and colleagues reported that loss of
1p (and 1p/19q co-deletion) predicts a better response to
procarbazine-lomustine-vincristine chemotherapy and a
longer survival in patients with AO [13]. These findings
have been reproduced in many subsequent studies,
including prospective and randomized phase III trials
[14, 15]. Moreover, oligodendroglial tumors with loss of
1p/19q showed a response to treatment with the alkyl-
ating drug TMZ and radiotherapy, indicating its predic-
tive value for a broader spectrum of therapeutic regimens
[16–18]. These results indicated that patients with AOA
or GBMO-LTS had a significantly longer survival time
than GBMO-STS might be linked to the higher incidence
of 1p/19q co-deletion.
As elaborated by experts, IDH1 mutation was associ-
ated with a better outcome in patients with low-grade
diffuse gliomas, AA, GBM and had been shown to be a
powerful independent prognostic factor for prolonged
survival [19, 20]. IDH1/2 genes encode for the cytosolic
and mitochondrial nicotinamide adenine dinucleotide
phosphate (NADPH)-dependent isocitrate dehydrogenase
enzymes which play an vital role in the citric acid cycle.
Wild-type IDH1/2 isozymes catalyze the oxidative car-
boxylation of isocitrate to a-ketoglutarate and reduce
NADP? to NADPH during this process [21, 22]. Both
the a-ketoglutarate and the released NADPH are known
cell defenders against oxidative damage. Mutated IDH
gene decreases the ability of the IDH enzyme to catalyze
the conversion of isocitrate to a-ketoglutarate and leads
to a decreased quantity of a-ketoglutarate and NADPH,
making the cell more susceptible to oxidative stress [23].
In the present study, patients of GBMO-STS showed
lower IDH1 mutation rate compared with AOA or
GBMO-LTS, which suggested that the survival of
GBMO-STS would be shorter than AOA or GBMO-LTS.
However, the incidence of IDH1 mutation, in our cohort,
was a little lower in comparison to the reports from
Europe or America, but it was similar with Jiang’s report
which displayed the frequency of IDH1/2 mutation in
Chinese AOA was 45.8 %. Ethnic differences might
partly explain it [24–26]. Inevitably, the phenomenon
might, to some extent, due to our imperfect experiment
method. Of interest, there was no significant difference
of IDH1 mutation rate between GBMO-STS and GBM.
It documented that the incidence of IDH1 mutation could
not be a parameter which resulted in the difference of
survival time between the two groups.
Presence of 1q, 19p polysomy contributed to the dismal
prognosis of GBMO-STS
Univariate analysis revealed that polysomy for 1q and 19p
were associated with the dismal prognosis of patients with
high-grade gliomas. These findings were in consistent with
many previous reports. Snuderl et al. [27] reported that
polysomy for chromosomes 1 and 19 predicted earlier
recurrence in anaplastic oligodendrogliomas with concur-
rent 1p/19q loss. Wiens et al. [28] documented that com-
bined polysomy was associated with higher histological
tumor grade and conferred poor survival likelihood. They
concluded polysomy of 1q and/or 19p was a relatively
frequent occurrence in oligodendrogliomas and usually
conferred an unfavorable outcome. In the present study,
intergroup comparison showed GBMO-STS harbored
higher frequency of 1q, 19p polysomy than AOA or GBM.
It might partly interpret the phenomenon that GBMO-STS
with a median OS of merely 10.0 months which was sig-
nificantly shorter than AOA or even GBM. Another pos-
sible explanation for the dismal prognosis of GBMO was
that these tumors were in fact small cell GBM which
exhibited shorter survival time than GBM and could mimic
GBMO. Considering this issue, a pathology re-evaluation
was performed. Though the pathology consultation result
revealed these specimens were GBMO, the EGFR ampli-
fication information was the best means to making the
distinction between small cell GBM and GBMO. Because
of the limited experimental resource, the EGFR amplifi-
cation was not available in our laboratory. Finally, higher
incidence of polysomy for 1q and 19p might be a potential
parameter which contributed to the survival time
B12 months of GBMO-STS.
From the above, experts, all over the world, in regard of
the prognostic value of an oligodendrogial component in
glioblastomas couldn’t arrive at a consensus (Table 4).
Based on the data displayed in the study, we speculate that
GBMO, a heterogeneous group with considerable survival
variant, directly being regarded as ‘‘glioblastomas’’ with
relatively favorable outcome remains a subject needs further
inquiry. Because there is a subtype GBMO with concurrent
polysomy for chromosomes 1 and 19 exhibits shorter sur-
vival than GBM. When encountered with such subtype of
patients, perhaps taking the polysomy for chromosomes 1
and 19 into account would be more reasonable in guiding the
individual therapy in clinic care. Another important issue is
that FISH seems to be more suitable for assessing loss of 1p
and 19q compared with polymerase chain reaction (PCR)
with regard to clinical significance of polysomy. Because,
compared with PCR-based loss of heterozygosity (LOH)
assays, additional polysomy information can be gleaned
from the FISH analysis.
402 J Neurooncol (2014) 116:395–404
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Study limitation
The small sample of GBMO-STS which would weaken the
conviction of this study to some extent. So we will enlarge
our sample for the further inquiry in the future. It was also
a limitation that the EGFR amplification information was
absent in distinguishing GBMO from small cell GBM.
Conclusions
Patients with GBMO concurrent with polysomy for chro-
mosomes 1 and 19 always confers an unfavorable prog-
nosis which needs our extra attention in clinic.
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